This is a preview of subscription content, log in via an institution to check access.
Notes
2016 US dollars
Reference
Hao Y, et al. Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. 59th Annual Meeting and Exposition of the American Society of Hematology : (plus oral presentation) abstr. 609, 9 Dec 2017. Available from: URL: https://ash.confex.com/ash/2017/webprogram/Paper105771.html
Rights and permissions
About this article
Cite this article
Tisagenlecleucel value-based prices estimated for r/r ALL. PharmacoEcon Outcomes News 794, 33 (2018). https://doi.org/10.1007/s40274-018-4631-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4631-x